Please type a plus sign (+) inside this box ->

PTO/SB/08A (10-96) Approv or use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons ollection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 09/498,704 pplication Number INFORMATION DISCLOSUNE Filing Date 02/07/2000 STATEMENT BY APPLICANT First Named Inventor Paul S. Uster Group Art Unit 1616 (use as many sheets as necessary) Unknown Examiner Name of |1 Attorney Docket Number Sheet 5325-0162.30

				U.S. PATENT DOC	UMENTS	
	07-	U.S. Pater	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner initials*	Cite No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
					 	
						
						
	-4				+	
	-				 	· · · · · ·
					 	
\longrightarrow	\dashv		- - 		 	
-	\dashv				 	
					 	
						
-				- H		
				-77-7-1		
	-		- 			
	\dashv				1	
					-	

				FO	REIGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No.1	Office ³	Foreign Patent Do	Cument Kind Code (if known		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
M	1	wo!	96 25147 A	-	Sequus Pharm. Inc.	08/22/1996		\Box
711	2	wo!	99 30561 A	7/	Nexstar Pharma.	06/24/1999		
1/11	3	wo	00 43045 A	7	Photogen Inc.	07/27/2000		\square
								Ш
		Ш						┦
		\sqcup			<u> </u>		·	ш
		\sqcup						\vdash
		\vdash			ļ		******	\vdash
•		1 1						

Examiner Signature	Kula	Date Considered	707

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box =

Approx or use through 10/31/99 OMB 0651-0031

Approx or use through

٠.	Under the Paperwork Reduction Act of 1995, no persons are reduced to res	spond to a gallection of information	on unless it contains a valid OMB control number.
-	Substitute for form 1449B/PTO	.00	mplete if Known
		Application Number	09/498,704
	INFORMATION DISCLOSURE	Filing Date	02/07/2000
	STATEMENT BY APPLICANT	First Named Inventor	Paul S. Uster
	OTATEMENT BY ATTEMANT	Group Art Unit	1616
	(use as many sheets as necessary)	Examiner Name	Unknown
	Sheet 1 of 1	Attorney Docket Number	5325-0162 30

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
la	1	HARRINGTON ET AL., "Stealth Liposome Encapsulated Iododeoxyuridine (SLIUdR) for Targeted Radiosensitisation in Xenograft Tumours," British J. of Cancer, p. 35, V.78(2)	/
		· ·	
			<u> </u>

Examiner Signature	Kulu	Date Considered	10/00	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

	<u>.</u>		_	•		
		ATTY. DO	_	SERIA	L NO.	EC
INFORMATION DISCLOS	SURE CITATION	5325-	0162.30	09/49	8,704	
Form PTO-1449 (M	Modified)					NOV 🖠
(Use several sheets	if necessary)					1
OIPE		APPLICAN	T -		TEC	H CENTR
/ <u>%</u>		į	Uste	r, et a	1.	H CENTER
NOV 2 7 2000 ()		FILING D	ATE	GROUP		
		Februar	y 7, 200	0	1615	
4. 49	U.S. PATENT DOC	UMENTS				
RADEMARK						
Examiner Document	Date Name		Class	Subclass	Filing	Date
Initial Number					If Approp	oriate
						T
					<u> </u>	
				-		·
						1
	FOREIGN PATENT DO	CUMENTS				1
Document	Date Counti	ry	Class	Subclass	Transla	tion
Number WO 96/25147 08	/22/96 PCT				<u> </u>	₽
ω_{k}						
	7/24/99 PCT					
WO 00/43045 07	/27/00 PCT					
OTHER ART (Inclu	uding Author, Title, Da	ate, Pertin	nent Page	s, Etc.)		ŀ
Harrington, K.	, et al., "Stealth	liposom	e encap	sulated		-
iododeoxyuridi	ne (SLIUdR) for ta	rgeted r	adioser	sitisat	ion in	
xenograft tumo	urs" British Journ	al of Ca	ncer vo	ol. <u>78</u> s	uppl. 2	pp./
35 abstract# P	28 (1998).					
				-		
XAMINER	рате с	CONSIDERED		,		
EXAMINER KAMA	DATE C	CONSIDERED	9	701		

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO. 5325-0162.30 SERIAL NO. 09/498,704

RECEIVED

APPLICANT

Uster, et al.

MAY 1 2000

FILING DATE February 7, 2000

2000 GROUP

161**TECH CENTER** 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Document	Date	Name	Class	Subclass	Filing Date
Initial	Number					If Appropriate
1/2	4,942,226	07/17/90	Saari			
	5,077,034	12/31/91	Kassis et al.			
	5, 223,263	06/29/93	Hostetler et al.			
	5,728,684	03/17/98	Cheng et al.		_	
VZ	5,811,073	09/22/98	Kassis et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translat	ion
						Yes	No
W	5058879 A	03/09/93	, JP		í	Derwent abstract only	
M	95/15154	06/08/95	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

[w	Atcher, R.W., et al., "Halogenated Pyrimidines as Radiosensitizers for High-LET Radiation" Radiation Research 117:351-355 (1989).
	Epstein, A.H., et al., "Tumour Radiosensitization with the Halogenated Pyrimidines 5'-bromo- and 5'-iododeoxyuridine" BJR Supplement 24:209-214 (1992).
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Hardman, et al. (eds), McGraw-Hill, New York, pp. 1247-1248 (1996).
	Hofer, K.G., "Nouvelles Et Travaux" Bull Cancer (Paris) 67(3):343-353 (1980).
	Mori, A., et al., "Immunotargeting of Liposomes Containing Lipophilic Antitumor Prodrugs" <i>Pharmaceutical Research</i> 10(4):507-514 (1993).
	Mori, A., et al., "Characterization of Organ-specific Immunoliposomes for Delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model" Cancer Chemother Pharmacol 35:447-456 (1995).

30 F Scherphof, G.L., et al., "Lipid Flow Phenomena Between Liposomes, Lipoproteins and Cell Membranes; Applications in Drug Delivery" Liposome Dematics, Braun-Falco, Korting and Maibach (eds), Springer Verlag: Berlin, pp. 11-19 (1992). Scherphof, G.L., et al., "Liposomes in Chemo- and Immunotherapy of Cancer" Lipids 22(11):891-896 (1987). IPE Schwendener, R.A., et al., "5'-0-Palmitoyl- and 3',5'-0-Dipalmitoy1-5-Fluoro-2'-Deoxyuridine - Novel Lipophilic Analogues of 5'-Fluoro-2'-Deoxyuridine: Synthesis, Incorporation into Liposomes and Preliminary Biological Results" Biochemical and TO TO EMARY 1 5 200h Biophysical Research Communications 126(2):660-666 (1985). Schwendener, R.A., "The Preparation of Large Volumes of Momogeneous, Sterile Liposomes Containing Various Lipophilic Cytostatic Drugs by the Use of a Capillary Dialyzer" Cancer Drug Delivery 3(2):123-129 (1986). Shenoy, M.A. and Singh, B.B., "Chemical Radiosensitizers in Cancer Therapy" Cancer Investigation 10(06):533-551 (1992). Smolin, G., et al., "Idoxuridine-Liposome Therapy for Herpes Simplex Keratitis" American Journal of Ophthalmology 91:220-225 (1981). Supersaxo, A., et al., "The Antitumour Effect of Lipophilic Derivatives of 5-fluoro-2'-deoxyuridine Incorporated into Liposomes" J Microencapsulation 5(1):1-11(1988). Van Borssum Waalkes, M., et al., "In-vitro Stability and Cytostatic Activity of Liposomal Formulations of 5-fluoro-2'-deoxyuridine and its Diacylated Derivatives" Biochimica et Biophysica Acta 1148:161-172 (1993). Van Borssum Waalkes, M., et al., "In vivo Distribution and Antitumour Activity of Liposomal 3', 5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine" J Microencapsulation 9(3):335-346 (1992). Van Borssum Waalkes, M., Lipophilic Derivatives of 5-Fluoro-2'-Deoxyuridine as Liposomal Anticancer Agents pp. 7-159 (1992). Van Borssum Waalkes, M. and Scherphof, G.L., "Liposome-Incorporated 3', 5'-0-Dipalmitoyl-5-Fluoro-2'-Deoxyuridine as a Slow-Release Anti-Tumor Drug Depot in Rat Liver Macrophages" Selective Cancer Therapeutics $\underline{6}(1):15-22$ (1990). Van Borssum Waalkes, M., et al., "Toxicity of Liposomal 3'-5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine in Mice" Anti-Cancer Drug Design 13:291-305 (1998). DATE CONSIDERED EXAMINER

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.